Revagenix, Inc.

This early-stage trial tests an inhaled drug called Rev-56 in healthy volunteers and in people with non-cystic fibrosis bronchiectasis who have chronic Pseudomonas aeruginosa lung infections. The study checks whether the drug is safe and how the body processes it, comparing Rev-5…